Skip to main content
NCBI home page
Frontiers in Bioengineering and Biotechnology logoLink to Frontiers in Bioengineering and Biotechnology
. 2020 Apr 29;8:371. doi: 10.3389/fbioe.2020.00371

Cell Membrane Coated-Biomimetic Nanoplatforms Toward Cancer Theranostics

Tingting Li 1,2, Xiang Qin 1,2, Yichao Li 1, Xue Shen 3, Shun Li 1,2, Hong Yang 1,2, Chunhui Wu 1,2, Chuan Zheng 4, Jie Zhu 4, Fengming You 4, Yiyao Liu 1,4,*
PMCID: PMC7202082  PMID: 32411690

Abstract

Research of nanotechnology for cancer therapy and diagnosis extends beyond drug delivery into the targeted site or surveillance the distribution of nanodrugs in vivo or distinction tumor tissue from normal tissue. To satisfy the clinic needs, nanotheranostic platform should hide the surveillance by immune system and the sequestration by filtration organs (i.e., liver and spleen). Use of biologically derived cellular components in the fabrication of nanoparticles can hide these barriers. In this review, we update the recent progress on cell membrane-coated nanoparticles for cancer theranostics. We hope this review paper can inspire further innovations in biomimetic nanomedicine.

Keywords: cancer, theranostic, cell membrane, biomimetic, nanocomplex

Introduction

Cancer is known to be the most aggressive malignancy to humans, and definitely the major cause of death worldwide (Roma-Rodrigues et al., 2019). In the fight against cancer, half of the battle is won based on its early detection (Phillips et al., 2014; Ye et al., 2014). As we know, new treatments such as phototherapy and immunotherapy have received considerable attention due to their obvious advantages than the conventional therapies. Phototherapy including photothermal therapy (PTT) and photodynamic therapy (PDT), they rely on the phototherapeutic agents in cooperation with laser irradiation to selectively kill cancer cells, while ignoring the healthy cells in the dark (Liu X. et al., 2018; Li W. et al., 2019). However, monotherapies have limited efficacy. Consequently, multiple approaches have been provided to be a promising route for cancer therapy (Min et al., 2019; Yue et al., 2019).

Theranostics based on nanotechnology strategies is a new form of cancer treatment, they can integrate the conventional or the new therapeutic modalities and diagnostic functions such as magnetic resonance (MR) imaging, photoacoustic (PA) imaging, positron emission tomography (PET) imaging or fluorescence imaging etc. into one single carrier and assist in the management of cancer (Li et al., 2016; Li T. et al., 2019). Theranostics showed a number of advantages such as improved diagnosis, tumor specific delivery of drugs, reduced damage to healthy tissue.

In the last few decades, theranostic nanoplatforms gained great progress in basic research and produced a large number of excellent publications (Yang H. et al., 2018; Shen et al., 2019). Scientists developed numerous theranostic nanosystems based on organic nanoparticles, inorganic nanoparticles, micelles, dendrimer, and got good effect in cell studies and animal studies (Ray et al., 2018; Yang J. et al., 2018; Shao et al., 2019; Xu et al., 2019; Bort et al., 2020). These theranostic nanoplatforms were modified with polymer, antibody, peptide or other functional molecules to obtain profuse biological functions, such as targeting, long circulation, biocompatibility, and immune escaping (Yang et al., 2017; Liu S. et al., 2019; Xie X. et al., 2019; Wu et al., 2020).

But the application of theranostic nanoplatforms in the clinical trials have been disappointing. Two vital problems need to be solved urgently, the first one is the biosafety of theranostic platforms should be systemically evaluated. The second one, which our final goal, is getting the expected effect in the clinic (Choi et al., 2012; Liu Y. et al., 2018; Vankayala and Hwang, 2018; Jing et al., 2019). As a consequence, we should develop theranostic nanosystems that closely mimic the biological composition of our bodies and make the efficiency of theranostic nanoplatforms maximally.

Cell membrane coated biomimetic nanoplatforms are often semi-biological (or semi-artificial) which take advantages of their inherited property, such as biointerfacing, self-identification and signal transduction can escape from biological barriers such as immune clearance, opsonization, and negotiation with vascular system (Evangelopoulos and Tasciotti, 2017; Chen et al., 2019; Jin et al., 2019; Madamsetty et al., 2019; Yan et al., 2019; Ma et al., 2020a). These theranostic nanoplatforms have the potential to play an important role in cancer diagnosis and treatment (Bose et al., 2018a; Li Z. et al., 2018; Meng et al., 2018; Sung et al., 2019; Ye S. et al., 2019). This review article will introduce the recent efforts on the rational design of cell membrane-based biomimetic nanosystem for cancer diagnosis and treatment, we highlight the strategies of engineering and application in Figure 1.

FIGURE 1.

FIGURE 1

Open in a new tab

The application of cell membrane-coated nanoparticles for cancer therapy and imaging.

Development of Cell Membrane-Coated Biomimetic Theranostic Nanoplatform

Hu et al. (2011) first reported that they used a top-down method to synthesize erythrocyte membrane camouflaged nanoparticles for long-circulating cargo delivery. Since that, cell membrane, not just erythrocyte membrane but cancer cell membrane, stem cell membrane, platelet membrane, endothelial cell membrane, etc. were used for coating materials of nanoparticles (Kroll et al., 2017; Narain et al., 2017; Pasto et al., 2019; Zhou et al., 2019). Owning the advantages of the native functionalities originating from cell membrane including reserved antigens and cell membrane structure, biomimetic nanoparticles can acquire special functions, such as ligand recognition and targeting, long blood circulation, and immune escaping (Chen Z. et al., 2016; Feng et al., 2019; Meng et al., 2019). In a valuable review paper, the authors discussed in detail the advantages of different cell membrane camouflaged nanoparticles (Chen Z. et al., 2016). In this paper, we briefly summarized the recent progress in the development of biomimetic cell membrane camouflaged nanocomplex for cancer theranostic. We also demonstrated the highlight in the recent research about biomimetic cell membrane camouflaged nanocomplex on cancer theranostic in the following sections.

Red Blood Cells Membrane Camouflaged Theranostic Nanocomplex

Red blood cells (RBCs) are the primary transport of oxygen through the blood in body, they can live up to 120 days in humans, and are nature’s long circulating carriers (Hsieh et al., 2015; Fang et al., 2018; Liu J.M. et al., 2018). It is reported that RBCs are the ideal membrane modification materials because of the abundant proteins, glycans, and receptors on the RBCs membrane surfaces which can bypass the immune system attack (Rao et al., 2017; Ren et al., 2017; Su et al., 2017). For example, CD47 (integrin-associated protein) is a self- marker of RBCs which can interface with its corresponding receptor, prevent the clearing from the bloodstream by macrophages (Oldenborg et al., 2000; Xie J. et al., 2019). The intact RBCs membrane could directly modify on the surface of nanoparticles without any complex process, and the final nanoparticle still inherits the functions of RBCs (Jiang et al., 2017; Lian et al., 2019; Yang et al., 2019). In one instance, Li et al. used Ag2S quantum dots (QD), a good fluorescence imaging agent with ideal photothermal and photodynamic therapeutic effects under laser irradiation as a sonosensitizer. Pluronic F-127-modified Ag2S QDs were wrapped in RBC vesicles for enzyme-augmented sonodynamic therapy (SDT). RBC membranes coating in this system could prolong the circulation time of the probe, and catalyzed endogenous H2O2 by the catalase in RBCs to ameliorate tumor hypoxia. Besides, Ultrasound (US) could also promote tumor blood flow, relieve the hypoxic condition, and enhance the SDT effect of the probe. This study provide a promising strategy for the future design of a multifunctional theranostic nanoplatform (Li et al., 2020). Wang and co-workers designed RBC based probe (RBCp) for NIR-II fluorescence bioimaging-guided tumor surgery and light-triggered O2 release to enhance PDT efficiency. In vivo study showed that RBCp could provide efficient tumor targeting and laser-responsive O2 release to enhance the PDT efficiency of popliteal lymph node metastasis under the guidance of NIR II fluorescence bioimaging (Figure 2; Wang et al., 2019).

FIGURE 2.

FIGURE 2

Open in a new tab

NIR-II fluorescence imaging guided tumor surgery of RBCp. NIR-II fluorescence bioimaging results of epidermal tumors with sizes of 7 mm3 (row one), 3 mm3 (row two), and the NIR-II bioimaging results of popliteal lymph node metastasis (row three). Reproduced with permission from Wang et al. (2019). Copyright © Ivyspring International Publisher.

Cancer Cell Membrane Camouflaged Theranostic Nanocomplex

Inspired by the reality that nanotheranostic nanoplatform should have good biocompatibility and the ability of homologous targeting, cancer cell membrane coated nanotheranostic nanoplatform have been recently getting more and more attention (Li S.Y. et al., 2018; Zhang N. et al., 2018; Zhang W. et al., 2019; Kumar et al., 2019). In particular, cancer cells are robust and easy to multiply culture in vitro for mass membrane collection, cancer cell membrane expressing “markers of self” and “self-recognition molecules” can be removed from cancer cells and coated on nanoparticles, demonstrating homologous targeting and immune escape ability (Bose et al., 2018b; Shao et al., 2018; Cai et al., 2019; Harris et al., 2019; Liu C. et al., 2019; Nie et al., 2019; Zhang D. et al., 2019). Wang and coauthors designed HeLa cell membrane coated nanocomposites for Fluorescence/MR dual-modal imaging guided PDT. These HeLa membrane coated nanocomposites (denoted as mGZNs) showed enhanced in vivo anti-tumor targeting efficiency of 80.6% for HeLa cells, providing new strategies to develop nanocomposites for visualized cancer theranostics (Wang et al., 2020). Zhu and coworkers designed a magnetic iron oxide based nanosystem coated with different types of cracked cancer cell membranes (CCCM). This nanocomplex showed the excellent self-recognition internalization by the source cancer cell lines in vitro and in vivo. As shown in Figure 3A, cellular internalization of UM-SCC-7, and HeLa cell membrane coated MNP@DOX@NPs (termed as MNP@DOX@UM-SCC-7 and MNP@DOX@HeLa, respectively) was studied upon 3 h coincubation with four cell lines including UM-SCC-7, HeLa, HepG2, and COS7 cells. An amazing outcome was found that the fluorescence intensity originating from two CCCM coated nanoparticles was far superior in the corresponding source cells over those in heterotypic cells. To conform the in vivo tumor self-targeting ability toward homologous tumors, the authors intravenously injected mice bearing UM-SCC-7 tumor on the right hind limb with MNP@DOX@CCCM NPs prepared with different cell membranes. As shown in Figure 3B, In the group injected with MNP@DOX@UM-SCC-7 showed more intratumor fluorescence intensity than other groups (Zhu et al., 2016).

FIGURE 3.

FIGURE 3

Open in a new tab

(A) Confocal laser scanning microscope (CLSM) images of four cell lines including UM-SCC-7, HepG2, HeLa, and COS7 cells upon 2 h coincubation with MNP@DOX@UM-SCC-7 and MNP@DOX@HeLa. Scale bars: 20 μm. (B) Schematic illustration of UM-SCC-7 tumor-bearing mouse model treated with DOX and various cell membrane cloaked MNP@DOX@CCCM. (C) In vivo fluorescence images at 24 h post intravenous injection with MNP@DOX@CCCM (a: @UM-SCC-7; b: @COS7; c: @HeLa) and DOX (d) with an equivalent DOX dosage (2.5 mg/kg). Reproduced with permission from Zhu et al. (2016). Copyright © 2016 American Chemical Society.

Stem Cell Membrane Camouflaged Theranostic Nanocomplex

Stem cell membrane is another natural biomimetic membrane coating that have been used for cancer theranostics (Ma et al., 2019; Shin et al., 2019; Zhao et al., 2019). Stem cell membrane with its inherent tumortropism coating onto nanoparticles has enabled the fabrication of nanocarriers with similar targeting functionality (Letko Khait et al., 2019; Wu et al., 2019). In an example of umbilical cord-derived mesenchymal stem cell coated polymeric nanoplatform, poly(lactic-co-glycolic acid) (PLGA) nanoparticle loaded with Doxorubicin (NP-Dox) were coated with cord-derived mesenchymal stem cell membrane for tumor-targeted delivery of chemotherapy. The coating membrane significantly enhanced the cellular uptake efficiency of PLGA nanoparticles and the tumor cell killing efficacy of PLGA-encapsulated doxorubicin (Yang N. et al., 2018). In another study, bone marrow derived mesenchymal stem cell membrane was coated on gelatin nanogels (termed as SCMGs) for tumor-targeted drug delivery. SCMGs showed high cancer cellular uptake of DOX compared with gelatin-DOX and free DOX. To monitor the in vivo distribution of nanogels, a near-infrared fluorescent dye, Cyanine7 (Cy7) was loaded into both SCMGs and bare gelatin nanogels. After intravenous injection of different nanogel formulations in tumor bearing mice, the average fluorescence signal in the SCMGs treated mice was notably higher than that obtained in the group treated with bare gelatin (Gao et al., 2016).

Cancer-Associated Fibroblast Membrane Camouflaged Theranostic Nanocomplex

Cancer associated fibroblast membrane has recently obtained more and more attention as membrane coating materials. As reported, cancer-associated fibroblasts are recognized as a key obstacle to cancer treatment (Chen B. et al., 2016). On the one hand, they construct a protecting physical barrier to impede tumor cells uptake of antitumor drugs. One the other hand, they secrete abundant growth factors and cytokines to activate correlative signaling pathways for promoting tumor angiogenesis, progression, initiation, metastasis, and resistance. Studies have shown that used cancer-associated fibroblast membrane coated nanoparticles to deliver therapeutic agents could target and kill cancer-associated fibroblasts, and depleted tumor-stroma biological interactions and in turn led to enhanced therapy (Ji et al., 2015, 2016; Li L. et al., 2018; Kovacs et al., 2020). Li et al. developed semiconducting polymer nanoparticles (SPNs) coated with activated fibroblast membranes (denoted as AF-SPN) for enhanced multimodal cancer phototheranostics. In this study, uncoated SPN (uSPN) nanoparticles and the cancer cell membrane coated SPN (CCSPN) nanoparticles were as control group. To demonstrate the photodiagnostic potential of nanoparticles in vivo, different nanoparticles were intravenously injected into 4T1 tumor-bearing mice, and their NIR fluorescence and PA images were obtained. As shown in Figures 4A,B. AF-SPN facilitated homologous targeting ability, and allowed to specifically target cancer-associated fibroblasts. The experiment results demonstrated that AF-SPN provided higher accumulation in tumor tissues than both the uSPN and CC-SPN, and amplified NIR fluorescence and photoacoustic (PA) signals for tumor imaging (Li J. et al., 2018).

FIGURE 4.

FIGURE 4

Open in a new tab

In vivo fluorescence and PA imaging of tumors in living mice after treatment with different complexes. (A) In vivo NIR fluorescence images of 4T1 tumor-bearing mice at different time points after systemic administration of uSPN, CC-SPN, and AF-SPN via tail vein injection. The tumor was on the right side of the back, as indicated by the white dashed circles. (B) Representative PA maximum imaging projection of 4T1 tumors in living mice at 0, 24, 48, and 72 h after systemic administration of different complexes via tail vein injection. Reproduced with permission from Li J. et al. (2018). Copyright © 2018 American Chemical Society.

Hybrid Cells Membrane Camouflaged Theranostic Nanocomplex

Based on the concept that membranes from various cell types carry different properties. Research Scientists developed two types of cell membrane fusion coating made nanoparticles inherit and amplify the properties of both source cells (Liang et al., 2018; Ye H. et al., 2019). The two types of pre-extracted cell membranes were mixed together at appropriate protein weight ratios at 37°C to facilitate membrane fusion. For instance, Dehaini et al. fabricated RBC-platelet hybrid membrane-coated nanoparticles. This dual-membrane-coated nanoplatform exhibited long circulation, excellent biocompatibility and suitability for further in vivo exploration (Dehaini et al., 2017). In another study, firstly, the researchers get hybrid cells. Briefly, cancerous 4T1 cells and dendritic cells (DCs) were mixed at a ratio of 1:2 in the phosphate buffer (PBS) solution containing 50% polyethylene glycol (PEG) (MW = 4000) and 10% dimethyl sulfoxide (DMSO) after 2 min fusion at 38°C, the cells were washed with medium to remove the PEG and DMSO. After fused cells were cultured for 6-day, the cytomembranes (FMs) of hybrid cells were collected. FMs were coated on metal organic framework (PCN-224) by ultrasonic treatment in a cold water bath until the solution was transparent. The obtained hybrid cell membrane coated nanoparticles were further purified by centrifugation to remove the free FMs. The authors showed that this hybrid cell membrane coated nanoparticles can not only inherit the specifically targeted ability to homologous tumors from parent 4T1 cells but also obtained the enhanced ability of immune induction owing to the high expression of a whole array of tumor antigens in FMs (Figure 5; Liu W.L. et al., 2019).

FIGURE 5.

FIGURE 5

Open in a new tab

Schematic illustration showed the preparation of PCN@FM for combined tumor therapy. Reproduced with permission from Liu W.L. et al. (2019). Copyright © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Other Cells Membrane Camouflaged Theranostic Nanocomplex

Thanks to the advantages of cell membrane coated nanosystem for cancer theranostic, more and more types of cell membrane be used as coating materials according to their self-nature and the clinical need. Platelet, derived from megakaryocytes, is an indispensable component of blood stream, participate in many physiological activities and play an important role, including coagulation, hemostasis, the body’s innate immune response, and cancer metastasis (Li Z. et al., 2018). P-Selectin is a cell adhesion protein, found predominantly in endothelial cells and platelets. Upon platelet activation, it can get exposed on the platelet membrane (PM) surface, and specifically bind to CD44 receptors upregulated on the surface of cancer cells (Bergstrand et al., 2019). Inspired by these properties of platelets, Hu et al. developed a PM coated core-shell nanovehicle (denoted as PM-NV) for codelivery of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) and doxorubicin (Dox). The nanocomplex was defined as TRAIL-Dox-PM-NV. TRAIL is one of the most important extracellular activators of apoptosis, induces apoptosis of tumor cells by binding to the death receptors (DR4, DR5) on the cell surface; while Dox can damage the nuclear DNA of cancer cells to trigger the intrinsic apoptosis signaling pathway. PM coating enhanced drug accumulation by active targeting based on the affinity between PM and overexpressed CD44 receptors on the cancer cells. TRAIL-Dox-PM-NV showed synergetic antitumor efficacy to MDA-MB-231 tumor-bearing nude mice (Hu et al., 2015).

At present, the great benefits of immunotherapies in oncology are evident, T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumor antigens have demonstrated tremendous success in eradicating hematologic malignancies (e.g., CD19 CARs in leukemias) (Herzyk and Haggerty, 2018; Labanieh et al., 2018). However, this success was not observed in solid tumors, and the reasons for this are being investigated (Newick et al., 2017). Considering these situations, Ma et al. combined cell membrane coating nanotechnology with CAR-T therapy to treat hepatocellular carcinoma (HCC), due to the high tumor specificity of CAR-T cells and the advantage of cell membrane-camouflaged nanoparticles in drug delivery. They used Glypican-3 (GPC3) targeting CAR-T to prepare CAR-T membranes (CMs). GPC3, a 580-AA heparin sulfate proteoglycan, is a key biomarker for early diagnosis of HCC due to its overexpression in 75% of HCC samples, but not in healthy liver or other normal tissues (Dargel et al., 2015; Zhang Q. et al., 2018). Near-infrared (NIR) dye IR780, was loaded in mesoporous silica nanoparticles (MSNs) to form a core. The IR780 dye with NIR absorbance can produce heat under laser for PTT. IR780-loaded MSNs (IMs) were coated with a layer of pre-prepared CAR-T membranes using an extrusion method to fabricate tumor specific CAR-T Cell membrane-coated nanoparticles (CIMs). CIMs inherited the tumor targeting and a long circulation ability from the membrane cloaking, and demonstrated enhanced anti-tumor capabilities with minimal systematic toxicity both in vitro and vivo (Ma et al., 2020b).

Conclusion and Perspectives

This review has highlighted the current development of cell membrane coated nanoparticles for cancer theranostic. We present the overview of the application of RBC membrane coating materials, cancer cell membrane materials, stem cell membrane materials, and others on cancer theranostic. Cell membrane coated nanoparticles have shown unique advantages to enhance cancer therapy and imaging, but they still have many problems need to be overcome in translating to the clinic. For example, the yield of cell membrane extraction is low, it often needs to culture a huge number of cells, and just harvest a small amount of cell membrane, therefore cell isolation and purification approach still requires future improvement. There are various proteins are present on the cell membrane. It also needs to identify the potential proteins and remove unwanted proteins. Although a large number of cell membrane coated nanoparticles have been developed for the integration of cancer diagnosis and treatment, how many of their specific functions have been developed, and whether they have realized the functions envisioned by researchers, are the urgent problems need to be proven. All in all, there is the need to establish standard protocols for obtaining and testing cell membrane coating production. However, the current evaluation of the therapeutic and diagnostic effect of cell membrane coated nanoparticles have been limited in preclinical studies. we hope that the clinical translation of cell membrane coated nanoparticles can be accelerated, which will make a positive impact on human health and be of great economic value.

Author Contributions

TL contributed to the design, reorganize the figures, and writing the manuscript. XQ, YL, and XS contributed to research the literature. SL, HY, CW, CZ, JZ, and FY helped with editing the manuscript. YL conceived and designed the outline of this review. All the authors read and approved the final manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

Funding. This work was supported, in part or in whole, by the National Natural Science Foundation of China (81671821, U19A2006, 11772088, 31700811, 11802056, 31800780, 11972111, and 31900940), the China Postdoctoral Science Foundation (2018M640904 and 2019T120831), the Sichuan Science and Technology Program (2019YJ0183 and 2019YJ0184), and the Fundamental Research Funds for the Central Universities (ZYGX2019J117).

References

  1. Bergstrand J., Xu L., Miao X., Li N., Oktem O., Franzen B., et al. (2019). Super-resolution microscopy can identify specific protein distribution patterns in platelets incubated with cancer cells. Nanoscale 11 10023–10033. 10.1039/c9nr01967g [DOI] [PubMed] [Google Scholar]
  2. Bort G., Lux F., Dufort S., Cremillieux Y., Verry C., Tillement O. (2020). EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: from animal to human with theranostic AGuIX nanoparticles. Theranostics 10 1319–1331. 10.7150/thno.37543 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bose R. J. C., Paulmurugan R., Moon J., Lee S. H., Park H. (2018a). Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics. Drug Discov. Today 23 891–899. 10.1016/j.drudis.2018.02.001 [DOI] [PubMed] [Google Scholar]
  4. Bose R. J. C., Uday Kumar S., Zeng Y., Afjei R., Robinson E., Lau K., et al. (2018b). Tumor cell-derived extracellular vesicle-coated nanocarriers: an efficient theranostic platform for the cancer-specific delivery of anti-miR-21 and imaging agents. ACS Nano 12 10817–10832. 10.1021/acsnano.8b02587 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cai D., Liu L., Han C., Ma X., Qian J., Zhou J., et al. (2019). Cancer cell membrane-coated mesoporous silica loaded with superparamagnetic ferroferric oxide and Paclitaxel for the combination of Chemo/Magnetocaloric therapy on MDA-MB-231 cells. Sci. Rep. 9:14475. 10.1038/s41598-019-51029-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen B., Dai W., Mei D., Liu T., He B., He B., et al. (2016). Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. J. Control. Release 241 68–80. 10.1016/j.jconrel.2016.09.014 [DOI] [PubMed] [Google Scholar]
  7. Chen Z., Wang Z., Gu Z. (2019). Bioinspired and biomimetic nanomedicines. Acc Chem. Res. 52 1255–1264. 10.1021/acs.accounts.9b00079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chen Z., Zhao P., Luo Z., Zheng M., Tian H., Gong P., et al. (2016). Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano 10 10049–10057. 10.1021/acsnano.6b04695 [DOI] [PubMed] [Google Scholar]
  9. Choi K. Y., Liu G., Lee S., Chen X. (2012). Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 4 330–342. 10.1039/c1nr11277e [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dargel C., Bassani-Sternberg M., Hasreiter J., Zani F., Bockmann J. H., Thiele F., et al. (2015). T cells engineered to express a T-cell receptor specific for Glypican-3 to recognize and kill hepatoma cells in vitro and in mice. Gastroenterology 149 1042–1052. 10.1053/j.gastro.2015.05.055 [DOI] [PubMed] [Google Scholar]
  11. Dehaini D., Wei X., Fang R. H., Masson S., Angsantikul P., Luk B. T., et al. (2017). Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv. Mater. 29:10.1002/adma.201606209. 10.1002/adma.201606209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Evangelopoulos M., Tasciotti E. (2017). Bioinspired approaches for cancer nanotheranostics. Nanomedicine 12 5–7. 10.2217/nnm-2016-0374 [DOI] [PubMed] [Google Scholar]
  13. Fang R. H., Kroll A. V., Gao W., Zhang L. (2018). Cell membrane coating nanotechnology. Adv. Mater. 30:e1706759. 10.1002/adma.201706759 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Feng Q., Yang X., Hao Y., Wang N., Feng X., Hou L., et al. (2019). Cancer cell membrane-biomimetic nanoplatform for enhanced sonodynamic therapy on breast cancer via autophagy regulation strategy. ACS Appl. Mater. Interfaces. 11 32729–32738. 10.1021/acsami.9b10948 [DOI] [PubMed] [Google Scholar]
  15. Gao C., Lin Z., Jurado-Sanchez B., Lin X., Wu Z., He Q. (2016). Stem cell membrane-coated nanogels for highly efficient in vivo tumor targeted drug delivery. Small 12 4056–4062. 10.1002/smll.201600624 [DOI] [PubMed] [Google Scholar]
  16. Harris J. C., Scully M. A., Day E. S. (2019). Cancer cell membrane-coated nanoparticles for cancer management. Cancers 11:10.1002/adma.201606209. 10.3390/cancers11121836 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Herzyk D. J., Haggerty H. G. (2018). Cancer immunotherapy: factors important for the evaluation of safety in nonclinical studies. AAPS J. 20:28. 10.1208/s12248-017-0184-3 [DOI] [PubMed] [Google Scholar]
  18. Hsieh C. C., Kang S. T., Lin Y. H., Ho Y. J., Wang C. H., Yeh C. K., et al. (2015). Biomimetic acoustically-responsive vesicles for theranostic applications. Theranostics 5 1264–1274. 10.7150/thno.11848 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hu C. M. J., Zhang L., Aryal S., Cheung C., Fang R. H., Zhang L. F. (2011). Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U.S.A. 108 10980–10985. 10.1073/pnas.1106634108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hu Q., Sun W., Qian C., Wang C., Bomba H. N., Gu Z. (2015). Anticancer platelet-mimicking nanovehicles. Adv. Mater. 27 7043–7050. 10.1002/adma.201503323 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ji T., Ding Y., Zhao Y., Wang J., Qin H., Liu X., et al. (2015). Peptide assembly integration of fibroblast-targeting and cell-penetration features for enhanced antitumor drug delivery. Adv. Mater. 27 1865–1873. 10.1002/adma.201404715 [DOI] [PubMed] [Google Scholar]
  22. Ji T., Zhao Y., Ding Y., Wang J., Zhao R., Lang J., et al. (2016). Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation. Angew. Chem. Int. Ed. Engl. 55 1050–1055. 10.1002/anie.201506262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Jiang Q., Luo Z., Men Y., Yang P., Peng H., Guo R., et al. (2017). Red blood cell membrane-camouflaged melanin nanoparticles for enhanced photothermal therapy. Biomaterials 143 29–45. 10.1016/j.biomaterials.2017.07.027 [DOI] [PubMed] [Google Scholar]
  24. Jin J., Krishnamachary B., Barnett J. D., Chatterjee S., Chang D., Mironchik Y., et al. (2019). Human cancer cell Membrane-coated biomimetic nanoparticles reduce fibroblast-mediated invasion and metastasis and induce T-Cells. ACS Appl. Mater. Interfaces 11 7850–7861. 10.1021/acsami.8b22309 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Jing X., Xu Y., Liu D., Wu Y., Zhou N., Wang D., et al. (2019). Intelligent nanoflowers: a full tumor microenvironment-responsive multimodal cancer theranostic nanoplatform. Nanoscale 11 15508–15518. 10.1039/c9nr04768a [DOI] [PubMed] [Google Scholar]
  26. Kovacs D., Igaz N., Marton A., Ronavari A., Belteky P., Bodai L., et al. (2020). Core-shell nanoparticles suppress metastasis and modify the tumour-supportive activity of cancer-associated fibroblasts. J. Nanobiotechnol. 18:18. 10.1186/s12951-020-0576-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kroll A. V., Fang R. H., Zhang L. (2017). Biointerfacing and applications of cell membrane-coated nanoparticles. Bioconjug. Chem. 28 23–32. 10.1021/acs.bioconjchem.6b00569 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kumar P., Treuren T. V., Ranjan A. P., Chaudhary P., Vishwanatha J. K. (2019). In vivo imaging and biodistribution of near infrared dye loaded brain-metastatic-breast-cancer-cell-membrane coated polymeric nanoparticles. Nanotechnology 30:265101. 10.1088/1361-6528/ab0f46 [DOI] [PubMed] [Google Scholar]
  29. Labanieh L., Majzner R. G., Mackall C. L. (2018). Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2 377–391. 10.1038/s41551-018-0235-9 [DOI] [PubMed] [Google Scholar]
  30. Letko Khait N., Malkah N., Kaneti G., Fried L., Cohen Anavy N., Bronshtein T., et al. (2019). Radiolabeling of cell membrane-based nano-vesicles with (14)C-linoleic acid for robust and sensitive quantification of their biodistribution. J. Control. Release 293 215–223. 10.1016/j.jconrel.2018.12.005 [DOI] [PubMed] [Google Scholar]
  31. Li C., Yang X. Q., An J., Cheng K., Hou X. L., Zhang X. S., et al. (2020). Red blood cell membrane-enveloped O2 self-supplementing biomimetic nanoparticles for tumor imaging-guided enhanced sonodynamic therapy. Theranostics 10 867–879. 10.7150/thno.37930 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Li J., Zhen X., Lyu Y., Jiang Y., Huang J., Pu K. (2018). Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics. ACS Nano 12 8520–8530. 10.1021/acsnano.8b04066 [DOI] [PubMed] [Google Scholar]
  33. Li L., Zhou S., Lv N., Zhen Z., Liu T., Gao S., et al. (2018). Photosensitizer-encapsulated ferritins mediate photodynamic therapy against cancer-associated fibroblasts and improve tumor accumulation of nanoparticles. Mol. Pharm. 15 3595–3599. 10.1021/acs.molpharmaceut.8b00419 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Li S. Y., Xie B. R., Cheng H., Li C. X., Zhang M. K., Qiu W. X., et al. (2018). A biomimetic theranostic O2-meter for cancer targeted photodynamic therapy and phosphorescence imaging. Biomaterials 151 1–12. 10.1016/j.biomaterials.2017.10.021 [DOI] [PubMed] [Google Scholar]
  35. Li T., Shen X., Geng Y., Chen Z., Li L., Li S., et al. (2016). Folate-functionalized magnetic-mesoporous silica nanoparticles for drug/gene codelivery to potentiate the antitumor efficacy. ACS Appl. Mater. Interfaces 8 13748–13758. 10.1021/acsami.6b02963 [DOI] [PubMed] [Google Scholar]
  36. Li T., Shi S., Goel S., Shen X., Xie X., Chen Z., et al. (2019). Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer. Acta Biomater. 89 1–13. 10.1016/j.actbio.2019.02.031 [DOI] [PubMed] [Google Scholar]
  37. Li W., Yang J., Luo L., Jiang M., Qin B., Yin H., et al. (2019). Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat. Commun. 10:3349. 10.1038/s41467-019-11269-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Li Z., Hu S., Cheng K. (2018). Platelets and their biomimetics for regenerative medicine and cancer therapies. J. Mater. Chem. B 6 7354–7365. 10.1039/C8TB02301H [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Lian Y., Wang X., Guo P., Li Y., Raza F., Su J., et al. (2019). Erythrocyte membrane-coated arsenic trioxide-loaded sodium alginate nanoparticles for tumor therapy. Pharmaceutics 12:21. 10.3390/pharmaceutics12010021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Liang H., Huang K., Su T., Li Z., Hu S., Dinh P. U., et al. (2018). Mesenchymal stem cell/red blood cell-inspired nanoparticle therapy in mice with carbon tetrachloride-induced acute liver failure. ACS Nano 12 6536–6544. 10.1021/acsnano.8b00553 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Liu C., Wang D., Zhang S., Cheng Y., Yang F., Xing Y., et al. (2019). Biodegradable biomimic copper/manganese silicate nanospheres for chemodynamic/photodynamic synergistic therapy with simultaneous glutathione depletion and hypoxia relief. ACS Nano 13 4267–4277. 10.1021/acsnano.8b09387 [DOI] [PubMed] [Google Scholar]
  42. Liu S., Wang L., Zhang M., Tao K., Wang B., Lin M., et al. (2019). Tumor microenvironment-responsive nanoshuttles with sodium citrate modification for hierarchical targeting and improved tumor theranostics. ACS Appl. Mater. Interfaces 11 25730–25739. 10.1021/acsami.9b07957 [DOI] [PubMed] [Google Scholar]
  43. Liu J. M., Zhang D. D., Fang G. Z., Wang S. (2018). Erythrocyte membrane bioinspired near-infrared persistent luminescence nanocarriers for in vivo long-circulating bioimaging and drug delivery. Biomaterials 165 39–47. 10.1016/j.biomaterials.2018.02.042 [DOI] [PubMed] [Google Scholar]
  44. Liu W. L., Zou M. Z., Liu T., Zeng J. Y., Li X., Yu W. Y., et al. (2019). Expandable immunotherapeutic nanoplatforms engineered from cytomembranes of hybrid cells derived from cancer and dendritic cells. Adv. Mater. 31:e1900499. 10.1002/adma.201900499 [DOI] [PubMed] [Google Scholar]
  45. Liu X., Su H., Shi W., Liu Y., Sun Y., Ge D. (2018). Functionalized poly(pyrrole-3-carboxylic acid) nanoneedles for dual-imaging guided PDT/PTT combination therapy. Biomaterials 167 177–190. 10.1016/j.biomaterials.2018.03.030 [DOI] [PubMed] [Google Scholar]
  46. Liu Y., Zhen W., Jin L., Zhang S., Sun G., Zhang T., et al. (2018). All-in-one theranostic nanoagent with enhanced reactive oxygen species generation and modulating tumor microenvironment ability for effective tumor eradication. ACS Nano 12 4886–4893. 10.1021/acsnano.8b01893 [DOI] [PubMed] [Google Scholar]
  47. Ma J., Zhang S., Liu J., Liu F., Du F., Li M., et al. (2019). Targeted drug delivery to stroke via chemotactic recruitment of nanoparticles coated with membrane of engineered neural stem cells. Small 15:e1902011. 10.1002/smll.201902011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Ma W., Sha S. N., Chen P. L., Yu M., Chen J. J., Huang C. B., et al. (2020a). A cell membrane-targeting self-delivery chimeric peptide for enhanced photodynamic therapy and in situ therapeutic feedback. Adv. Healthc Mater. 9:e1901100. 10.1002/adhm.201901100 [DOI] [PubMed] [Google Scholar]
  49. Ma W., Zhu D., Li J., Chen X., Xie W., Jiang X., et al. (2020b). Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics 10 1281–1295. 10.7150/thno.40291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Madamsetty V. S., Mukherjee A., Mukherjee S. (2019). Recent trends of the bio-inspired nanoparticles in cancer theranostics. Front. Pharmacol. 10:1264. 10.3389/fphar.2019.01264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Meng Q.-F., Cheng Y.-X., Huang Q., Zan M., Xie W., Sun Y., et al. (2019). Biomimetic immunomagnetic nanoparticles with minimal nonspecific biomolecule adsorption for enhanced isolation of circulating tumor cells. ACS Appl. Mater. Interfaces 11 28732–28739. 10.1021/acsami.9b10318 [DOI] [PubMed] [Google Scholar]
  52. Meng Q. F., Rao L., Zan M., Chen M., Yu G. T., Wei X., et al. (2018). Macrophage membrane-coated iron oxide nanoparticles for enhanced photothermal tumor therapy. Nanotechnology 29:134004. 10.1088/1361-6528/aaa7c7 [DOI] [PubMed] [Google Scholar]
  53. Min H., Wang J., Qi Y., Zhang Y., Han X., Xu Y., et al. (2019). Biomimetic metal-organic framework nanoparticles for cooperative combination of antiangiogenesis and photodynamic therapy for enhanced efficacy. Adv. Mater. 31:e1808200. 10.1002/adma.201808200 [DOI] [PubMed] [Google Scholar]
  54. Narain A., Asawa S., Chhabria V., Patil-Sen Y. (2017). Cell membrane coated nanoparticles: next-generation therapeutics. Nanomedicine 12 2677–2692. 10.2217/nnm-2017-0225 [DOI] [PubMed] [Google Scholar]
  55. Newick K., O’Brien S., Moon E., Albelda S. M. (2017). CAR T cell therapy for solid tumors. Annu. Rev. Med. 68 139–152. 10.1146/annurev-med-062315-120245 [DOI] [PubMed] [Google Scholar]
  56. Nie D., Dai Z., Li J., Yang Y., Xi Z., Wang J., et al. (2019). Cancer-cell-membrane-coated nanoparticles with a yolk-shell structure augment cancer chemotherapy. Nano Lett. 20 936–946. 10.1021/acs.nanolett.9b03817 [DOI] [PubMed] [Google Scholar]
  57. Oldenborg P. A., Zheleznyak A., Fang Y. F., Lagenaur C. F., Gresham H. D., Lindberg F. P. (2000). Role of CD47 as a marker of self on red blood cells. Science 288 2051–2054. [DOI] [PubMed] [Google Scholar]
  58. Pasto A., Giordano F., Evangelopoulos M., Amadori A., Tasciotti E. (2019). Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy. Clin. Transl. Med. 8:8. 10.1186/s40169-019-0224-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Phillips E., Penate-Medina O., Zanzonico P. B., Carvajal R. D., Mohan P., Ye Y., et al. (2014). Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med. 6:260ra149. 10.1126/scitranslmed.3009524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Rao L., Meng Q.-F., Bu L.-L., Cai B., Huang Q., Sun Z.-J., et al. (2017). Erythrocyte membrane-coated upconversion nanoparticles with minimal protein adsorption for enhanced tumor imaging. ACS Appl. Mater. Interfaces 9 2159–2168. 10.1021/acsami.6b14450 [DOI] [PubMed] [Google Scholar]
  61. Ray S., Li Z., Hsu C. H., Hwang L. P., Lin Y. C., Chou P. T., et al. (2018). Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics. Theranostics 8 6322–6349. 10.7150/thno.27828 [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Ren H., Liu J., Li Y., Wang H., Ge S., Yuan A., et al. (2017). Oxygen self-enriched nanoparticles functionalized with erythrocyte membranes for long circulation and enhanced phototherapy. Acta Biomater. 59 269–282. 10.1016/j.actbio.2017.06.035 [DOI] [PubMed] [Google Scholar]
  63. Roma-Rodrigues C., Pombo I., Raposo L., Pedrosa P., Fernandes A. R., Baptista P. V. (2019). Nanotheranostics targeting the tumor microenvironment. Front. Bioeng. Biotechnol. 7:197. 10.3389/fbioe.2019.00197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Shao C., Xiao F., Guo H., Yu J., Jin D., Wu C., et al. (2019). Utilizing polymer micelle to control dye J-aggregation and enhance its theranostic capability. iScience 22 229–239. 10.1016/j.isci.2019.11.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Shao D., Li M., Wang Z., Zheng X., Lao Y. H., Chang Z., et al. (2018). Bioinspired diselenide-bridged mesoporous silica nanoparticles for dual-responsive protein delivery. Adv. Mater. e1801198. 10.1002/adma.201801198 Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
  66. Shen X., Li T., Chen Z., Xie X., Zhang H., Feng Y., et al. (2019). NIR-light-triggered anticancer strategy for dual-modality imaging-guided combination therapy via a bioinspired hybrid PLGA nanoplatform. Mol. Pharm. 16 1367–1384. 10.1021/acs.molpharmaceut.8b01321 [DOI] [PubMed] [Google Scholar]
  67. Shin T. H., Lee D. Y., Ketebo A. A., Lee S., Manavalan B., Basith S., et al. (2019). Silica-coated magnetic nanoparticles decrease human bone marrow-derived mesenchymal stem cell migratory activity by reducing membrane fluidity and impairing focal adhesion. Nanomaterials 9:1475. 10.3390/nano9101475 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Su J., Sun H., Meng Q., Zhang P., Yin Q., Li Y. (2017). Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes. Theranostics 7 523–537. 10.7150/thno.17259 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Sung S. Y., Su Y. L., Cheng W., Hu P. F., Chiang C. S., Chen W. T., et al. (2019). Graphene quantum dots-mediated theranostic penetrative delivery of drug and photolytics in deep tumors by targeted biomimetic nanosponges. Nano Lett. 19 69–81. 10.1021/acs.nanolett.8b03249 [DOI] [PubMed] [Google Scholar]
  70. Vankayala R., Hwang K. C. (2018). Near-infrared-light-activatable nanomaterial-mediated phototheranostic nanomedicines: an emerging paradigm for cancer treatment. Adv. Mater. 30:e1706320. 10.1002/adma.201706320 [DOI] [PubMed] [Google Scholar]
  71. Wang J., Wang Z., Zhong Y., Zou Y., Wang C., Wu H., et al. (2020). Central metal-derived co-assembly of biomimetic GdTPP/ZnTPP porphyrin nanocomposites for enhanced dual-modal imaging-guided photodynamic therapy. Biomaterials 229:119576. 10.1016/j.biomaterials.2019.119576 [DOI] [PubMed] [Google Scholar]
  72. Wang P., Wang X., Luo Q., Li Y., Lin X., Fan L., et al. (2019). Fabrication of red blood cell-based multimodal theranostic probes for second near-infrared window fluorescence imaging-guided tumor surgery and photodynamic therapy. Theranostics 9 369–380. 10.7150/thno.29817 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Wu C., Tian Y., Zhang Y., Xu J., Wang Y., Guan X., et al. (2020). Acid-triggered charge-convertible graphene-based all-in-one nanocomplex for enhanced genetic phototherapy of triple-negative breast cancer. Adv. Healthc. Mater. 9:e1901187. 10.1002/adhm.201901187 [DOI] [PubMed] [Google Scholar]
  74. Wu M., Le W., Mei T., Wang Y., Chen B., Liu Z., et al. (2019). Cell membrane camouflaged nanoparticles: a new biomimetic platform for cancer photothermal therapy. Int. J. Nanomed. 14 4431–4448. 10.2147/IJN.S200284 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Xie J., Shen Q., Huang K., Zheng T., Cheng L., Zhang Z., et al. (2019). Oriented assembly of cell-mimicking nanoparticles via a molecular affinity strategy for targeted drug delivery. ACS Nano 13 5268–5277. 10.1021/acsnano.8b09681 [DOI] [PubMed] [Google Scholar]
  76. Xie X., Chen Y., Chen Z., Feng Y., Wang J., Li T., et al. (2019). Polymeric hybrid nanomicelles for cancer theranostics: an efficient and precise anticancer strategy for the codelivery of doxorubicin/miR-34a and magnetic resonance imaging. ACS Appl. Mater. Interfaces 11 43865–43878. 10.1021/acsami.9b14908 [DOI] [PubMed] [Google Scholar]
  77. Xu C., Nam J., Hong H., Xu Y., Moon J. J. (2019). Positron emission tomography-guided photodynamic therapy with biodegradable mesoporous silica nanoparticles for personalized cancer immunotherapy. ACS Nano 13 12148–12161. 10.1021/acsnano.9b06691 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Yan H., Shao D., Lao Y. H., Li M., Hu H., Leong K. W. (2019). Engineering cell membrane-based nanotherapeutics to target inflammation. Adv. Sci. 6:1900605. 10.1002/advs.201900605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Yang H., Chen Y., Chen Z., Geng Y., Xie X., Shen X., et al. (2017). Chemo-photodynamic combined gene therapy and dual-modal cancer imaging achieved by pH-responsive alginate/chitosan multilayer-modified magnetic mesoporous silica nanocomposites. Biomater. Sci. 5 1001–1013. 10.1039/c7bm00043j [DOI] [PubMed] [Google Scholar]
  80. Yang H., Shen X., Yan J., Xie X., Chen Z., Li T., et al. (2018). Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination therapy. Biomater. Sci. 6 2426–2439. 10.1039/c8bm00419f [DOI] [PubMed] [Google Scholar]
  81. Yang J., Lu W., Xiao J., Zong Q., Xu H., Yin Y., et al. (2018). A positron emission tomography image-guidable unimolecular micelle nanoplatform for cancer theranostic applications. Acta Biomater. 79 306–316. 10.1016/j.actbio.2018.08.036 [DOI] [PubMed] [Google Scholar]
  82. Yang N., Ding Y., Zhang Y., Wang B., Zhao X., Cheng K., et al. (2018). Surface functionalization of polymeric nanoparticles with umbilical cord-derived mesenchymal stem cell membrane for tumor-targeted therapy. ACS Appl. Mater. Interfaces 10 22963–22973. 10.1021/acsami.8b05363 [DOI] [PubMed] [Google Scholar]
  83. Yang Q., Xiao Y., Yin Y., Li G., Peng J. (2019). Erythrocyte membrane-camouflaged IR780 and DTX coloading polymeric nanoparticles for imaging-guided cancer photo-chemo combination therapy. Mol. Pharm. 16 3208–3220. 10.1021/acs.molpharmaceut.9b00413 [DOI] [PubMed] [Google Scholar]
  84. Ye D., Shuhendler A. J., Cui L., Tong L., Tee S. S., Tikhomirov G., et al. (2014). Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nat. Chem. 6 519–526. 10.1038/nchem.1920 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Ye H., Wang K., Wang M., Liu R., Song H., Li N., et al. (2019). Bioinspired nanoplatelets for chemo-photothermal therapy of breast cancer metastasis inhibition. Biomaterials 206 1–12. 10.1016/j.biomaterials.2019.03.024 [DOI] [PubMed] [Google Scholar]
  86. Ye S., Wang F., Fan Z., Zhu Q., Tian H., Zhang Y., et al. (2019). Light/pH-triggered biomimetic red blood cell membranes camouflaged small molecular drug assemblies for imaging-guided combinational chemo-photothermal therapy. ACS Appl. Mater. Interfaces 11 15262–15275. 10.1021/acsami.9b00897 [DOI] [PubMed] [Google Scholar]
  87. Yue W., Chen L., Yu L., Zhou B., Yin H., Ren W., et al. (2019). Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. Nat. Commun. 10:2025. 10.1038/s41467-019-09760-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Zhang D., Ye Z., Wei L., Luo H., Xiao L. (2019). Cell membrane-coated porphyrin metal-organic frameworks for cancer cell targeting and O2-evolving photodynamic therapy. ACS Appl. Mater. Interfaces 11 39594–39602. 10.1021/acsami.9b14084 [DOI] [PubMed] [Google Scholar]
  89. Zhang W., Yu M., Xi Z., Nie D., Dai Z., Wang J., et al. (2019). Cancer cell membrane-camouflaged nanorods with endoplasmic reticulum targeting for improved antitumor therapy. ACS Appl. Mater. Interfaces 11 46614–46625. 10.1021/acsami.9b18388 [DOI] [PubMed] [Google Scholar]
  90. Zhang N., Li M., Sun X., Jia H., Liu W. (2018). NIR-responsive cancer cytomembrane-cloaked carrier-free nanosystems for highly efficient and self-targeted tumor drug delivery. Biomaterials 159 25–36. 10.1016/j.biomaterials.2018.01.007 [DOI] [PubMed] [Google Scholar]
  91. Zhang Q., Han Z., Tao J., Zhao M., Zhang W., Li P., et al. (2018). An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis. Biomater. Sci. 7 159–167. 10.1039/c8bm01016a [DOI] [PubMed] [Google Scholar]
  92. Zhao Q., Hai B., Zhang X., Xu J., Koehler B., Liu F. (2019). Biomimetic nanovesicles made from iPS cell-derived mesenchymal stem cells for targeted therapy of triple-negative breast cancer. Nanomedicine 24:102146. 10.1016/j.nano.2019.102146 [DOI] [PubMed] [Google Scholar]
  93. Zhou J., Kroll A. V., Holay M., Fang R. H., Zhang L. (2019). Biomimetic nanotechnology toward personalized vaccines. Adv. Mater. 32:e1901255. 10.1002/adma.201901255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Zhu J. Y., Zheng D. W., Zhang M. K., Yu W. Y., Qiu W. X., Hu J. J., et al. (2016). Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett. 16 5895–5901. 10.1021/acs.nanolett.6b02786 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Bioengineering and Biotechnology are provided here courtesy of Frontiers Media SA

RESOURCES